{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:08:28Z","timestamp":1786990108966,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.healun.2005.01.010","type":"journal-article","created":{"date-parts":[[2005,3,16]],"date-time":"2005-03-16T07:14:06Z","timestamp":1110957246000},"page":"S196-S200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"S","title":["Recommendations for Use of Certican\u00ae (Everolimus) After Heart Transplantation: Results From a German and Austrian Consensus Conference"],"prefix":"10.1016","volume":"24","author":[{"given":"Manfred","family":"Hummel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2005.01.010_bib1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican\u00ae) 12-months safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2005.01.010_bib2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.healun.2005.01.010_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1053-2498(02)01106-3","article-title":"One-year results of an international, randomized double-blind study of everolimus vs azathioprine as adjunctive therapy to inhibit the decline of pulmonary function in stable lung or heart\/lung transplant recipients","volume":"22","author":"Snell","year":"2003","journal-title":"J Heart Lung Tranplant (abstract)"},{"key":"10.1016\/j.healun.2005.01.010_bib4","first-page":"9","article-title":"Everolimus in de novo cardiac transplant recipients","author":"Haverich","year":"2003","journal-title":"ISHLT 23rd annual meeting, April"},{"issue":"suppl A","key":"10.1016\/j.healun.2005.01.010_bib5","first-page":"19","article-title":"Everolimus reduces cardiac allograft vasculopathy in de novo heart transplant recipients","author":"Hauck","year":"2003","journal-title":"Can J Cardiol"},{"issue":"suppl 5","key":"10.1016\/j.healun.2005.01.010_bib6","first-page":"550","article-title":"24-Month results of a multicenter study of Certican\u00ae for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients","volume":"3","author":"Mancini","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2005.01.010_bib7","article-title":"Certican\u00ae SPC. Summary of product characteristics","year":"2003","journal-title":"Novartis Pharma AG"},{"key":"10.1016\/j.healun.2005.01.010_bib8","article-title":"Excellent renal function with concentration-controlled everolimus, reduced Neoral exposure and steroids in de novo kidney transplant recipients","author":"Minetti","year":"2003","journal-title":"European Society of Organ Transplantation (ESOT) meeting"},{"key":"10.1016\/j.healun.2005.01.010_bib9","article-title":"Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced Neoral exposure and Simulect","author":"Rigotti","year":"2003","journal-title":"European Society of Organ Transplantation (ESOT) meeting"},{"key":"10.1016\/j.healun.2005.01.010_bib10","series-title":"Everolimus (Certican\u00ae, RAD) is associated with a reduced incidence of CMV infections following renal transplantation","author":"Dantal","year":"2002"},{"key":"10.1016\/j.healun.2005.01.010_bib11","article-title":"One-year results of a multicenter, randomized, double-blind study of everolimus (RAD) vs azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients","author":"Vitulo","year":"2003","journal-title":"European Society of Organ Transplantation (ESOT) meeting"},{"key":"10.1016\/j.healun.2005.01.010_bib12","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1046\/j.1600-6143.2004.00601.x","article-title":"Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure effect modelling","volume":"4","author":"Starling","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2005.01.010_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2005.01.010_bib14","first-page":"1177","article-title":"Incomplete adherence after pediatric heart and heart-lung transplantation","volume":"17","author":"Serrano-Ikkos","year":"1998","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2005.01.010_bib15","unstructured":"Innofluor Certican\u00ae Assay System product insert. Catalog No. 0373290. Seradyn, Inc., Indianapolis, IN."},{"key":"10.1016\/j.healun.2005.01.010_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mcp.2001.118022","article-title":"Population pharmacokinetics of everolimus in de novo renal transplant patients","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.healun.2005.01.010_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1399-0012.1998.tb01098.x","article-title":"Two-hour cyclosporine level determination is the appropriate tool in monitoring Neoral therapy","volume":"12","author":"Cantarovich","year":"1998","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2005.01.010_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007890-199907150-00011","article-title":"Neoral monitoring by simplified sparse sampling area under the concentration-time curve","volume":"68","author":"Mahalati","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2005.01.010_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/00007890-199912270-00003","article-title":"Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients","volume":"68","author":"Cantarovich","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2005.01.010_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1053-2498(01)00565-4","article-title":"Monitoring of cyclosporine 2-hr post-dose and trough levels in heart transplantation","volume":"21","author":"Delgado","year":"2002","journal-title":"J Heart Lung Transplant"},{"issue":"suppl","key":"10.1016\/j.healun.2005.01.010_bib21","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.healun.2004.03.010","article-title":"Optimizing the immunosuppressive regimen in heart transplantation","volume":"23","author":"Eisen","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2005.01.010_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/0091270002239822","article-title":"Clinical development of an everolimus pediatric formulation","volume":"43","author":"Kovarik","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.healun.2005.01.010_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1517\/13543784.11.12.1845","article-title":"Review of the proliferation inhibitor SDZ RAD 001","volume":"11","author":"Nashan","year":"2002","journal-title":"Expert Opin Investig Drugs"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249805000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249805000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:09:51Z","timestamp":1760947791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249805000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S1053249805000689"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2005.01.010","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for Use of Certican\u00ae (Everolimus) After Heart Transplantation: Results From a German and Austrian Consensus Conference","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2005.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}